LIGAND PHARMACEUTICALS INC Quarterly Report Released - Here’s What You Should Know

Ligand Pharmaceuticals Incorporated
Quarter Ended June 30, 2025 – Investor Summary

Key Financial Metrics

• Total assets as of June 30, 2025: $948.6 million (up from $941.8 million at year-end 2024)
• Total stockholders’ equity: $828.5 million
• Cash, cash equivalents, and short-term investments: $245.0 million
• Revenues and other income (Q2 2025): $47.6 million, up 15% from $41.5 million in Q2 2024
• YTD 2025 revenue and other income: $93.0 million, up 28% from $72.5 million YTD 2024
• Q2 2025 net income: $4.8 million (basic EPS of $0.25 per share), compared to Q2 2024 net loss of ($51.9) million (basic EPS of ($2.88))
• YTD 2025 net loss: ($37.6) million, compared to net income of $34.2 million YTD 2024
• Operating cash flow (YTD 2025): ($9.6) million (outflow), compared to $32.0 million (inflow) for YTD 2024
• R&D expenses (YTD 2025): $56.7 million, up from $11.3 million in YTD 2024
• General & administrative expenses (YTD 2025): $39.0 million, up from $28.6 million in YTD 2024
• Shares outstanding as of August 5, 2025: 19,596,560

Revenue Drivers

• Royalties (Q2 2025): $36.4 million, up 57% from $23.2 million in Q2 2024; YTD 2025: $63.9 million
• Captisol sales (Q2 2025): $8.3 million; YTD 2025: $21.7 million
• Revenue from intangible royalty assets (Q2 2025): $30.1 million
• Notable royalty contributors include Kyprolis ($8.8 million), Filspari ($6.6 million), Vaxneuvance ($2.6 million), and new contributions from Qarziba ($5.9 million in Q2 2025)
• Income from financial royalty assets (Q2 2025): $6.3 million, up significantly from $559,000 in Q2 2024

Operating Results

• Q2 2025 operating income: $8.4 million, compared to an operating loss of ($19.1) million in Q2 2024
• Total operating costs and expenses (Q2 2025): $39.2 million, down from $60.6 million in Q2 2024 (mainly due to a $26.5 million impairment charge in Q2 2024)
• YTD 2025 operating expenses: $120.7 million (up from $88.6 million YTD 2024) largely due to increased R&D and G&A spending
• Non-operating income (Q2 2025): $2.8 million vs. ($46.3) million in Q2 2024; includes $939,000 gain from short-term investments

Liquidity & Capital Structure

• No balance drawn on $75 million revolving credit facility, $124.4 million remaining available credit
• Stock repurchase program remains authorized
• No events of default or violations of covenants reported

Business and Management Discussion

• Completed Pelthos Therapeutics merger in July 2025; Pelthos raised $50.1 million in equity; Pelthos launched Zelsuvmi (berdazimer), the first and only topical treatment for molluscum contagiosum
• $25 million strategic investment in Orchestra BioMed’s late-stage pipeline in August 2025
• Royalty portfolio updates include expanded agreements, new program launches, and continuing clinical milestone progress for partner programs such as Qtorin, Filspari, Rylaze, Agenus’ BOT/BAL, and others
• Acquisitions (Apeiron in July 2024), and new royalty investments (Castle Creek, Agenus) have diversified the royalty asset base and added derivative and milestone potential
• YTD 2025 cash outflows in operations driven by investments/acquisitions (Castle Creek) and higher R&D spending
• Company's cash position, investments, and liquidity remain strong and management believes they are sufficient to support operations and growth initiatives
• Ongoing stock-based compensation expense: $17.8 million for YTD 2025

Risks

• Litigation: Ongoing legal matters including civil complaints from 2019 and a complaint filed by CyDex Pharmaceuticals in 2024 (no new material risk updates since last annual report)
• Revenue concentration and variability: Revenues rely heavily on royalty streams from partners (e.g., Kyprolis, Filspari, Evomela); performance is subject to the commercial success and continued development of those products
• R&D volatility: Significant increase in R&D spend ($56.7 million YTD 2025 vs. $11.3 million in YTD 2024) tied to product development pipeline and acquisition integration
• Impairment history: Prior impairments ($26.5 million in Q2 2024 related to Takeda’s Soticlestat) illustrate asset risk from clinical trial outcomes or regulatory setbacks
• Market risk: Company is exposed to market risks from equity investment values (e.g., Viking shares influence short-term investment results)
• Regulatory risk: The newly enacted "One Big Beautiful Bill Act" (July 2025) may impact the effective tax rate and other aspects of U.S. operations
• Integration risk: Ongoing acquisition activity (Apeiron, Castle Creek, etc.) creates operational and financial integration risks
• No material change in risk factors in Q2 2025 compared to prior disclosures; risks remain as described in prior filings

Conclusion
Ligand showed strong year-over-year revenue growth in Q2 and YTD 2025, with royalty and investment income leading results. Second quarter profit reflects portfolio and operational strength, though the year-to-date net loss reveals ongoing investment in growth (notably higher R&D spending) and volatility in investment and asset results. Cash and liquidity remain robust, supporting continued portfolio expansion and new royalty streams. However, investors should closely monitor litigation, integration of recent acquisitions, and variability in partner royalty streams and clinical results.

Visit Publicview AI to search and analyze millions of SEC filings using AI.